EntryPoint Capital’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

EntryPoint Capital’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,020	Closed	-$33.2K	–	1839
2023 Q4	$33.2K	Buy	+2,020	New	+$31.8K	0.03%	889

EntryPoint Capital's ORTX Position: Q1 2024 in Review

EntryPoint Capital sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2024, closing a stake of 2,020 shares — an estimated $33.2K sold.

EntryPoint Capital first reported a position in ORTX in Q4 2023 and held it in 1 quarter. The position peaked at $33.2K in Q4 2023. 0 funds tracked by Wall St. Rank hold ORTX as of Q1 2024.

EntryPoint Capital reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
EntryPoint Capital sold 2,020 Orchard Therapeutics plc American Depositary Shares shares in Q1 2024, an estimated $33.2K.
EntryPoint Capital first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2023 and held it in 1 quarter.
EntryPoint Capital's Orchard Therapeutics plc American Depositary Shares position peaked at $33.2K in Q4 2023.
0 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2024.

Based on EntryPoint Capital's 13F filing for Q1 2024, filed 14 May 2024.